ERBB2 and aneurysmal bone cyst: In the recently published phase III PHOEBE trial, the combination of pyrotinib/capecitabine was compared to lapatinib/capecitabine in patients with HER2-positive ABC who had previously received trastuzumab and taxane chemotherapy and reported improved median PFS with pyrotinib (12.5 vs. 6.8 months; HR 0.39 (95%CI 0.27–0.56) p < 0.0001), but a much higher rate of grade 3–4 toxicities, with up to 30% of the ITT population experiencing grade 3–4 diarrhoea, similar to that expected with capecitabine/neratinib [69].